Immunome (IMNM) Operating Leases (2023 - 2025)
Historic Operating Leases for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $4.0 million.
- Immunome's Operating Leases rose 6286.53% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 6286.53%. This contributed to the annual value of $4.8 million for FY2024, which is 25589.55% up from last year.
- According to the latest figures from Q3 2025, Immunome's Operating Leases is $4.0 million, which was up 6286.53% from $4.1 million recorded in Q2 2025.
- Over the past 5 years, Immunome's Operating Leases peaked at $4.8 million during Q1 2025, and registered a low of $1.2 million during Q1 2024.
- In the last 3 years, Immunome's Operating Leases had a median value of $2.5 million in 2024 and averaged $2.9 million.
- Its Operating Leases has fluctuated over the past 5 years, first tumbled by 1000.0% in 2024, then soared by 29552.24% in 2025.
- Quarter analysis of 3 years shows Immunome's Operating Leases stood at $1.3 million in 2023, then surged by 255.9% to $4.8 million in 2024, then dropped by 15.85% to $4.0 million in 2025.
- Its last three reported values are $4.0 million in Q3 2025, $4.1 million for Q2 2025, and $4.8 million during Q1 2025.